Innovent Biologics Inc IVBXF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Eli Lilly, InnoCare Sign Deal That Could Top $3 Billion
-
Innovent Biologics Shares Surge on Spero Deal That Could Be Worth $1.1 Billion
-
Chinese Biopharma Stocks Rally as Investors Favor Healthcare Over AI
-
Innovent Biologics Surges After Signing Up to $10.5 Billion Deal With Pfizer
-
Pfizer, Innovent Sign Licensing Deal to Develop 12 Cancer Drugs
-
Innovent Biologics Shares Surge After Swing to Profitability
-
Innovent Biologics Surges After Striking Partnership Deal with Eli Lilly
-
China's Innovent Strikes Cancer Drug Deal With Takeda for Up to $11.4 Billion — Update
Trading Information
- Previous Close Price
- $12.21
- Day Range
- $11.60–11.60
- 52-Week Range
- $9.10–15.01
- Bid/Ask
- $0.01 / $220,013.97
- Shares Outstanding
- 1.74B
- Market Cap
- $20.12B
- Volume/Avg
- 538 / 1,978
Key Statistics
- Price/Earnings (Normalized)
- 91.76
- Price/Sales
- 9.22
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong Stock Exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt’s main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Growth
- Total Number of Employees
- 8,754
- Website
- https://www.innoventbio.com
Competitors
Valuation
|
Metric
|
IVBXF
|
NVO
|
MRK
|
|---|---|---|---|
Price/Earnings (Normalized) | 91.76 | 8.75 | 45.87 |
Price/Book Value | 7.23 | 5.16 | 8.67 |
Price/Sales | 9.22 | 3.41 | 5.49 |
Price/Cash Flow | 63.15 | 8.16 | 16.49 |
Price/Earnings
IVBXF
NVO
MRK
Financial Strength
|
Metric
|
IVBXF
|
NVO
|
MRK
|
|---|---|---|---|
Quick Ratio | 2.48 | 0.64 | 0.71 |
Current Ratio | 2.68 | 0.87 | 1.32 |
Interest Coverage | 17.01 | — | 4.28 |
Quick Ratio
IVBXF
NVO
MRK
Profitability
|
Metric
|
IVBXF
|
NVO
|
MRK
|
|---|---|---|---|
Return on Assets (Normalized) | 6.48% | 21.31% | 6.27% |
Return on Equity (Normalized) | 13.49% | 59.99% | 16.68% |
Return on Invested Capital (Normalized) | 8.48% | 34.79% | 9.82% |
Return on Assets
IVBXF
NVO
MRK
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|RktysNH | LOCK|F&&B% | $136B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|sLSNvnV | LOCK|@<n% | $84B | |||
| Moderna Inc
MRNA
| LOCK|Y$qgJ< | LOCK|C# | $81B | |||
| argenx SE ADR
ARGX
| LOCK|Jy@x%LR | LOCK|X># | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|^xy^V> | LOCK|D# | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|JT<bL^ | LOCK|@rNP | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|VZ@!hj@ | LOCK|fgvln | $28B | |||
| Incyte Corp
INCY
| LOCK|^j^%@>G | LOCK|bh | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|<Db<<^ | LOCK|#^ | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|Y^>?h! | LOCK|$Jy | $14B |
United States